Compare
Amgen vs Protagonist Therapeutics (AMGN vs PTGX)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and Protagonist Therapeutics (PTGX) +69.5%; so far this year the figures are +40.7% and +51.2%.
Amgen is the larger company by market value, about 28.9 times the size of Protagonist Therapeutics.
On trailing earnings, AMGN trades at 26.7 times and PTGX at 28.0 times.
Revenue grew +8.2% at AMGN and +163.7% at PTGX over the last year.
AMGN yields 2.16%. PTGX pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | PTGX | |
|---|---|---|
| Price | $460.42 | $132.04 |
| 1-day | +0.03% | -2.38% |
| YTD | +40.67% | +51.18% |
| 1 year | +43.94% | +69.54% |
| 3 years | +76.51% | +773.86% |
| Market cap | $249.1B | $8.6B |
| P/E | 26.7 | 28.0 |
| P/S | 6.40 | 15.62 |
| P/B | 17.35 | 7.94 |
| Revenue growth | +8.20% | +163.70% |
| EPS growth | +33.30% | +624.60% |
| Gross margin % | 70.9 | — |
| Net margin % | 24.1 | 62.0 |
| ROE % | 65.4 | 31.5 |
| Debt / equity | 3.76 | 0.01 |
| FCF yield % | 3.8 | 1.3 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 0.93 |
| RSI (14) | 60.5 | 39.0 |
| Technical rating |